Cell Cycle Deregulation
1 clinical trials · Condition
◉ Watch Cell Cycle Deregulation
| Record | Firm | Date |
|---|---|---|
| Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial (NCT06363734) | Tianjin Medical University Cancer Institute and Hospital | 2024-04-09 |
Track Cell Cycle Deregulation automatically
Every clearance here is in the API, with alerts when new ones post.